JP7800914B2 - 脳送達のための合成脂質様材料 - Google Patents

脳送達のための合成脂質様材料

Info

Publication number
JP7800914B2
JP7800914B2 JP2022567136A JP2022567136A JP7800914B2 JP 7800914 B2 JP7800914 B2 JP 7800914B2 JP 2022567136 A JP2022567136 A JP 2022567136A JP 2022567136 A JP2022567136 A JP 2022567136A JP 7800914 B2 JP7800914 B2 JP 7800914B2
Authority
JP
Japan
Prior art keywords
compound
lipidoid
group
brain
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524747A5 (https=
JP2023524747A (ja
JPWO2021226092A5 (https=
Inventor
シュィ,チアオビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2023524747A publication Critical patent/JP2023524747A/ja
Publication of JP2023524747A5 publication Critical patent/JP2023524747A5/ja
Publication of JPWO2021226092A5 publication Critical patent/JPWO2021226092A5/ja
Application granted granted Critical
Publication of JP7800914B2 publication Critical patent/JP7800914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/20Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/11Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/12Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/26Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022567136A 2020-05-04 2021-05-04 脳送達のための合成脂質様材料 Active JP7800914B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019530P 2020-05-04 2020-05-04
US63/019,530 2020-05-04
PCT/US2021/030664 WO2021226092A1 (en) 2020-05-04 2021-05-04 Synthetic lipid-like materials for brain delivery

Publications (4)

Publication Number Publication Date
JP2023524747A JP2023524747A (ja) 2023-06-13
JP2023524747A5 JP2023524747A5 (https=) 2024-05-15
JPWO2021226092A5 JPWO2021226092A5 (https=) 2024-05-15
JP7800914B2 true JP7800914B2 (ja) 2026-01-16

Family

ID=78411889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567136A Active JP7800914B2 (ja) 2020-05-04 2021-05-04 脳送達のための合成脂質様材料

Country Status (11)

Country Link
US (2) US11666539B2 (https=)
EP (1) EP4146278A4 (https=)
JP (1) JP7800914B2 (https=)
KR (1) KR20230005367A (https=)
CN (1) CN115867262B (https=)
AU (1) AU2021267865A1 (https=)
BR (1) BR112022022358A2 (https=)
CA (1) CA3177508A1 (https=)
IL (1) IL297869A (https=)
MX (1) MX2022013865A (https=)
WO (1) WO2021226092A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2021226092A1 (en) 2020-05-04 2021-11-11 Trustees Of Tufts College Synthetic lipid-like materials for brain delivery
CN115232128B (zh) * 2022-08-15 2024-03-29 中国科学技术大学 一种咪唑并吡啶基脂质化合物及其制备方法与应用
CN116063245B (zh) * 2022-12-05 2024-09-10 南开大学 一种中心可降解的mRNA脂质体纳米粒子及其制备方法和应用
EP4638417A1 (en) 2022-12-22 2025-10-29 Nanovation Therapeutics Inc. Sulfur-containing ionizable lipids for the delivery of nucleic acids and other therapeutic agents
KR102758330B1 (ko) * 2023-02-22 2025-01-23 주식회사 서지넥스 황화물을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자
CN119119123A (zh) * 2023-06-08 2024-12-13 西南大学 长春胺类衍生物及其制备方法和应用
WO2026006906A1 (en) * 2024-07-02 2026-01-08 Ebovir Biotechnology Inc. Lipid nanoparticle delivery systems with enhanced stability

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083471A1 (en) 2000-05-02 2001-11-08 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
WO2004069240A2 (en) 2003-02-07 2004-08-19 Research & Innovation Soc. Coop. A. R. L. Use in therapy of endocannabinoid-like compounds
JP2006206723A (ja) 2005-01-27 2006-08-10 Adeka Corp 潤滑油組成物
JP2012519202A (ja) 2009-03-02 2012-08-23 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) 神経変性疾患を治療するためのインドール誘導体
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
CN105419632A (zh) 2015-12-28 2016-03-23 太仓耀华玻璃有限公司 一种led发光玻璃用高透光涂层及其制造方法
US20160346208A1 (en) 2015-05-28 2016-12-01 University Of South Carolina Dual responsive brain targeted nanoparticles and their applications
WO2019152848A1 (en) 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
WO2021022121A1 (en) 2019-07-31 2021-02-04 Trustees Of Tufts College Nitrilotriacetic acid-containing lipidoid nanoparticles
JP2023516977A (ja) 2020-03-02 2023-04-21 トラスティーズ オブ タフツ カレッジ 免疫細胞へのin vivoでのmRNA送達のためのイミダゾール系合成リピドイド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197274A (en) * 1962-03-05 1965-07-27 Gen Mills Inc Liquid-liquid recovery of metal values using hydroxyamine extractants
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
WO2021226092A1 (en) 2020-05-04 2021-11-11 Trustees Of Tufts College Synthetic lipid-like materials for brain delivery

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083471A1 (en) 2000-05-02 2001-11-08 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
WO2004069240A2 (en) 2003-02-07 2004-08-19 Research & Innovation Soc. Coop. A. R. L. Use in therapy of endocannabinoid-like compounds
JP2006206723A (ja) 2005-01-27 2006-08-10 Adeka Corp 潤滑油組成物
JP2012519202A (ja) 2009-03-02 2012-08-23 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) 神経変性疾患を治療するためのインドール誘導体
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US20160346208A1 (en) 2015-05-28 2016-12-01 University Of South Carolina Dual responsive brain targeted nanoparticles and their applications
CN105419632A (zh) 2015-12-28 2016-03-23 太仓耀华玻璃有限公司 一种led发光玻璃用高透光涂层及其制造方法
WO2019152848A1 (en) 2018-02-01 2019-08-08 Trustees Of Tufts College Lipid-like nanocomplexes and uses thereof
WO2021022121A1 (en) 2019-07-31 2021-02-04 Trustees Of Tufts College Nitrilotriacetic acid-containing lipidoid nanoparticles
JP2023516977A (ja) 2020-03-02 2023-04-21 トラスティーズ オブ タフツ カレッジ 免疫細胞へのin vivoでのmRNA送達のためのイミダゾール系合成リピドイド

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
BAHRI, J. et al.,Hydroamination of terminal alkynes with secondary amines catalyzed by copper: regioselective access to amines,Chemical Communications,2015年,Vol.51, No.(56),pp.11210-11212,DOI:10.1039/c5cc02677f
CHUMG,, Hyunho et al.,Cobalt-Rhodium Heterobimetallic Nanoparticle-Catalyzed N-Alkylation of Amines with Alcohols to Secondary and Tertiary Amines,The Journal of Organic Chemistry,2018年,Vol.83, No.15,pp.8533-8542,DOI: 10.1021/acs.joc.8b01109
DATABASE PUBCHEM COMPOUND [online] ,2019年,pp.1-5,30 August 2019 (2019-08-30), ANONYMOUS: "[2-(1H-indol-3-yl)ethyl]bis(3-methylbutyl)amine", XP055871249, retrieved from PUBCHEM Database accession no. 385316719
DATABASE PUBCHEM COMPOUND [online] ,2019年,pp.1-5,7 December 2019 (2019-12-07), ANONYMOUS: "SID 399019043", XP055871247, retrieved from PUBCHEM Database accession no. 399019043
DE JONGE, C. R. H. I.et al.,Antioxidative properties of phenyl-substituted phenols. Their role in synergistic combinations with β-activated thioethers,Advances in Chemistry Series,1978年,Vol.169,pp.399-425,(Stab. Degradation Polym.)
GUIMARASES, P. P. G. et al.,Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening,JOURNAL OF CONTROLLED RELEASE,2019年,Vol.316,pp.404-417,DOI:10.1016/j.jconrel.2019.10.028
HAYAMA, T. etal.,Binary Fluorous Alkylation of Biogenic Primary Amines with Perfluorinated Aldehyde Followed by Fluorous Liquid Chromatography-Tandem Mass Spectrometry Analysis,Analytical Chemistry ,2012年,Vol.84, No.19,pp.8407-8414,DOI:10.1021/ac3020092
KANG, Chuanqing et al.,Dehydrogenation and dehalogenation of amines in MALDI-TOF MS investigated by isotopic labeling,Journal of Mass Spectrometry,2013年,Vol.48, No.12,pp.1318-1324,DOI 10.1002/jms.3296
LI, J. et al.,Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles,ADVANCED MATERIALS ,2019年,31(33),pp.1-7,DOI: 10.1002/adma.201902575, Article No.1902575
LI,L. et al,Combinatorial Synthesis and High-Throughput Screening of Alkyl Amines for Nonviral Gene Delivery,Bioconjugate Chemistry,2013年,Vol.24, No.9,pp.1543-1551,DOI:10.1021/bc400158w
LUTZ, R. E. et al.,ANTIMALARIALS. ALPHA-PHENYL-BETA-DIALKYLAMINO ALCOHOLS,The Journal of Organic Chemistry,1947年,Vol.12, No.5,pp.617-620
MA, Feihe et al.,Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection,Science Advances ,2020年,Vol.6, No.30,pp.1-10,Article No.eabb4429
McBride, Ethan M.; et al.,Rapid experimental and computational determination of phenethylamine drug analogue lipophilicity,Forensic Chemistry,2016年,1,58-65
NARASHIMHAN, N. S. et al.,Lithiation of N, N-Dimethyl-β-Phenylethylamine,Tetrahedron Letters ,1966年,Vol.7 No.6,pp.603-605
REGISTRY(STN)[online],2019年,pp.1-3,2015.06.15[検索日 2025.03.08] CAS登録番号:2326011-44-1、1780667-68-6、1354305-59-1、1026098-17-8、959073-01-9、47634-70-8の化合物
SCHLOTT, R. J. et al.,Lithium amide catalyzed amine-olefin addition reactions,The Journal of Organic Chemistry ,1972年,Vol.37, No.26,pp.4243-4245
SREEDHAR, B. et al.,Regioselective ring opening of epoxides with amines using monodispersed silica nanoparticles in water,Journal of Molecular Catalysis A: Chemical,2007年,Vol.272, No.1-2,pp.159-163
STEPHEMS, M. D. et al.,Evaluation of ethyl N-(2-phenylathyl)carbamate analogues as biofilm inhibitors of methicillin resistant Staphylococcus aureus,Organic & Biomolecular Chemistry,2016年,Vol.14,pp.6853-6856,DOI: 10.1039/c6ob00706f
VETTER, W. et al.,Mass spectrometric investigation of some catenanes and macrocycles,Organic Mass Spectrometry,1977年,Vol.12, No.6,pp.351-69
WANG, Ming et al.,Combinatorially Designed Lipid-like Nanoparticles for Intracellular Delivery of Cytotoxic Protein for Cancer Therapy,Angewandte Chemie, International Edition,2014年,Vol.53, No.11,pp.2893-2898,DOI: 10.1002/anie.201311245
WU, Lipeng et al.,Efficient and Regioselective Ruthenium-catalyzed Hydro-aminomethylation of Olefins,Journal of the American Chemical Society,2013年,Vol.135, No.10,pp.3989-3996,DOI:10.1021/ja312271c

Also Published As

Publication number Publication date
US20220323369A1 (en) 2022-10-13
US11666539B2 (en) 2023-06-06
CN115867262A (zh) 2023-03-28
BR112022022358A2 (pt) 2023-01-31
US20210346307A1 (en) 2021-11-11
WO2021226092A1 (en) 2021-11-11
IL297869A (en) 2023-01-01
CA3177508A1 (en) 2021-11-11
JP2023524747A (ja) 2023-06-13
CN115867262B (zh) 2025-12-12
EP4146278A1 (en) 2023-03-15
EP4146278A4 (en) 2024-06-05
MX2022013865A (es) 2023-01-30
KR20230005367A (ko) 2023-01-09
AU2021267865A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7800914B2 (ja) 脳送達のための合成脂質様材料
JP7716112B2 (ja) 免疫細胞へのin vivoでのmRNA送達のためのイミダゾール系合成リピドイド
JP7383297B2 (ja) デンドリマー送達システムおよびそれを使用する方法
JP6762094B2 (ja) 薬剤のデリバリーのためのジスルフィド化合物
US20170056506A1 (en) Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
US20230322689A1 (en) Ionizable lipid compounds and lipid nanoparticle compositions
US20210315912A1 (en) Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US12503434B2 (en) Nitrilotriacetic acid-containing lipidoid nanoparticles
CN117777089B (zh) 脂质化合物和脂质纳米颗粒组合物
JP2025540651A (ja) 活性物質送達のための脂質化合物および組成物
US20240277851A1 (en) siRNA DELIVERY VECTOR
US20210315826A1 (en) Natural fluorescent polydedral amino acid crystals for efficient entrapment and systemic delivery of hydrophobic small molecules
WO2024187160A2 (en) Oxyanion azide-benzaldehyde acetal acid-degradable lipids
WO2024017254A1 (zh) 氨基脂质化合物、其制备方法和应用
ES2370638B1 (es) Dendrimeros como vehiculos no virales para terapia genica
WO2012017119A2 (es) Vectores no virales para terapia génica
TW202404568A (zh) 用於藥物遞送之化合物及組合物
CN121574072A (zh) 一种用于核酸递送的脂质材料及其应用
Devarakonda Poly (amidoamine)(PAMAM) dendrimers as solubility and permeation enhancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7800914

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150